Yohei Hosokawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yohei Hosokawa has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Genki Kidoguchi
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima
3 shared publications - Hiroki Kobayashi
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital , Hiroshima
3 shared publications - Naoya Oka
Department of Clinical Immunology and Rheumatology Hiroshima University Hospital Hiroshima Japan
3 shared publications - Shintaro Hirata
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
3 shared publications - Tomohiro Sugimoto
Department of Clinical Immunology and Rheumatology Hiroshima University Hospital Hiroshima Japan
3 shared publications - Yusuke Yoshida
Department of Clinical Immunology and Rheumatology Hiroshima University Hospital Hiroshima Japan
3 shared publications
Latest Publications
- 17 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70878
Seasonal Variation in Antineutrophil Cytoplasmic Antibody (ANCA)‐Associated Vasculitis Onset Before and During the Coronavirus Disease 2019 (COVID‐19) Pandemic: Findings From the Multicenter J‐CANVAS Registry
Aim: To investigate seasonal patterns in new‐onset antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV) during the coronavirus disease 2019 (COVID‐19) pandemic in Japan. Methods: We conducted a retrospective cohort study using data from the nationwide multicenter registry of patients with AAV. Patients newly diagnosed with AAV between 2017 and 2022 were included, comprising microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). We compared the seasonal distribution of AAV onset between the pre‐COVID‐19 (2017–2019) and COVID‐19 (2020–2022) periods. Results: A total of 871 patients were included (499 before and 372 during the COVID‐19 period). Poisson regression analysis revealed a seasonal variation in AAV onset in the pre‐COVID‐19 period ( p < 0.001), with lower onset in autumn [incidence rate ratio (IRR) 0.64, p < 0.001] and higher onset in spring and summer (IRR 1.16, p = 0.048 and IRR 1.23, p = 0.005) compared to winter. Importantly, a significant interaction between season and period ( p for interaction = 0.032) indicated that the seasonal pattern differed between periods, with a relative increase in spring (IRR 1.16, p = 0.010). In the subanalyses, seasonal variation was consistently observed in MPA, but not in GPA and EGPA. The interaction between season and period was not statistically significant in each disease group. Conclusion: AAV exhibited a clear seasonal pattern, which differed during the COVID‐19 period. However, these differences were not consistently observed across individual disease subtypes, and the factors underlying them remain unclear.
- 17 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70878
Seasonal Variation in Antineutrophil Cytoplasmic Antibody (ANCA)‐Associated Vasculitis Onset Before and During the Coronavirus Disease 2019 (COVID‐19) Pandemic: Findings From the Multicenter J‐CANVAS Registry
Aim: To investigate seasonal patterns in new‐onset antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV) during the coronavirus disease 2019 (COVID‐19) pandemic in Japan. Methods: We conducted a retrospective cohort study using data from the nationwide multicenter registry of patients with AAV. Patients newly diagnosed with AAV between 2017 and 2022 were included, comprising microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). We compared the seasonal distribution of AAV onset between the pre‐COVID‐19 (2017–2019) and COVID‐19 (2020–2022) periods. Results: A total of 871 patients were included (499 before and 372 during the COVID‐19 period). Poisson regression analysis revealed a seasonal variation in AAV onset in the pre‐COVID‐19 period ( p < 0.001), with lower onset in autumn [incidence rate ratio (IRR) 0.64, p < 0.001] and higher onset in spring and summer (IRR 1.16, p = 0.048 and IRR 1.23, p = 0.005) compared to winter. Importantly, a significant interaction between season and period ( p for interaction = 0.032) indicated that the seasonal pattern differed between periods, with a relative increase in spring (IRR 1.16, p = 0.010). In the subanalyses, seasonal variation was consistently observed in MPA, but not in GPA and EGPA. The interaction between season and period was not statistically significant in each disease group. Conclusion: AAV exhibited a clear seasonal pattern, which differed during the COVID‐19 period. However, these differences were not consistently observed across individual disease subtypes, and the factors underlying them remain unclear.
- Open Access
- 6 June 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (7) , 3957-3965
Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial
Introduction: Folic acid is routinely co-administered with methotrexate (MTX) to reduce toxicity; however, the optimal dose remains unclear. This study investigated whether increasing the weekly folic acid dose from 5 to 10 mg reduces MTX-related toxicity in patients receiving stable-dose MTX therapy. Methods: In this single-center, open-label, randomized controlled trial, 44 patients with rheumatic diseases on stable-dose MTX either received 10 mg (ARM-1) or 5 mg (ARM-2) of folic acid per week for 12 weeks. Liver damage, other MTX-related toxicities, and erythrocyte MTX-polyglutamate (MTX-PG) concentrations were compared between groups using logistic regression analysis or analysis of covariance. Japan Registry of Clinical Trials (number: jRCT1061230085). Results: Forty-two patients completed the study. The presence of liver damage at Day 84 did not differ significantly between the two groups (OR 0.41, 95% CI, 0.01–5.75, p = 0.506). Adjusted mean differences in aspartate transaminase and alanine transaminase at Day 84 between the groups were − 0.33 U/L (95% CI, − 2.68 to 2.02; p = 0.779) and − 0.44 U/L (95% CI, − 5.39 to 4.51; p = 0.859). Comparison of outcomes between groups at Day 84 showed no significant differences in any outcomes, except for fatigue severity (adjusted mean difference, − 0.87; 95% CI, − 1.71 to − 0.04; p = 0.041). Baseline fatigue was associated with baseline MTX-PG2 or MTX-PG1-2 concentrations (OR, 1.06; p = 0.049 or OR, 1.03; p = 0.040, respectively). Conclusions: Increasing folic acid dose to 10 mg/week showed little effect on reducing MTX-related toxicity, although it may improve fatigue in selected patients. Key Points • Increasing the weekly folic acid dose from 5 mg to 10 mg showed no additional benefit in reducing methotrexate-related toxicity in patients on stable-dose MTX. • Higher-dose folic acid was associated with improved fatigue severity, indicating a potential therapeutic option for patients who develop fatigue.
- 6 June 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (7) , 3957-3965
Open AccessEffect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial
Introduction: Folic acid is routinely co-administered with methotrexate (MTX) to reduce toxicity; however, the optimal dose remains unclear. This study investigated whether increasing the weekly folic acid dose from 5 to 10 mg reduces MTX-related toxicity in patients receiving stable-dose MTX therapy. Methods: In this single-center, open-label, randomized controlled trial, 44 patients with rheumatic diseases on stable-dose MTX either received 10 mg (ARM-1) or 5 mg (ARM-2) of folic acid per week for 12 weeks. Liver damage, other MTX-related toxicities, and erythrocyte MTX-polyglutamate (MTX-PG) concentrations were compared between groups using logistic regression analysis or analysis of covariance. Japan Registry of Clinical Trials (number: jRCT1061230085). Results: Forty-two patients completed the study. The presence of liver damage at Day 84 did not differ significantly between the two groups (OR 0.41, 95% CI, 0.01–5.75, p = 0.506). Adjusted mean differences in aspartate transaminase and alanine transaminase at Day 84 between the groups were − 0.33 U/L (95% CI, − 2.68 to 2.02; p = 0.779) and − 0.44 U/L (95% CI, − 5.39 to 4.51; p = 0.859). Comparison of outcomes between groups at Day 84 showed no significant differences in any outcomes, except for fatigue severity (adjusted mean difference, − 0.87; 95% CI, − 1.71 to − 0.04; p = 0.041). Baseline fatigue was associated with baseline MTX-PG2 or MTX-PG1-2 concentrations (OR, 1.06; p = 0.049 or OR, 1.03; p = 0.040, respectively). Conclusions: Increasing folic acid dose to 10 mg/week showed little effect on reducing MTX-related toxicity, although it may improve fatigue in selected patients. Key Points • Increasing the weekly folic acid dose from 5 mg to 10 mg showed no additional benefit in reducing methotrexate-related toxicity in patients on stable-dose MTX. • Higher-dose folic acid was associated with improved fatigue severity, indicating a potential therapeutic option for patients who develop fatigue.
- Open Access
- 24 February 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (5) , 778-785
Serum calprotectin elevation and interferon-α-induced neutrophil priming in macrophage activation syndrome associated with systemic lupus erythematosus: Clinical and experimental insights
Objectives: To clarify the diagnostic utility of serum calprotectin and gene expression in interferon (IFN)-α-activated neutrophils in macrophage activation syndrome (MAS) in patients with systemic lupus erythematosus (SLE). Methods: This single-centre, cross-sectional study analysed serum calprotectin levels in 47 patients with SLE (including eight with MAS) and 7 patients with adult-onset Still’s disease (AOSD) complicated with MAS as a reference population. In neutrophil-based experiments, mRNA expression levels of S100A8 and S100A9 were measured following stimulation with IFN-α or interleukin (IL)-1β. Results: Serum calprotectin levels were significantly elevated in patients with SLE-MAS compared to those with SLE without MAS and comparable to those in patients with AOSD-MAS. Calprotectin levels correlated with serum ferritin levels (rs = 0.49, P = .004), but not with anti-dsDNA antibodies or complement levels. At a cut-off value of 9184.4 ng/ml, serum calprotectin demonstrated sensitivity of 62.5% and specificity of 94.9% for identifying MAS. Recombinant IFN-α2a induced a dose-dependent increase in S100A8 and S100A9 expression in neutrophils, whereas recombinant interleukin-1β had no effect. Pre-treatment with an anti-IFN-α2 neutralising antibody effectively suppressed the IFN-α2a-induced expression of S100A8 and S100A9. Conclusions: Serum calprotectin, upregulated by IFN-α, may serve as a useful biomarker for diagnosing MAS in SLE.
- 24 February 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (5) , 778-785
Open AccessSerum calprotectin elevation and interferon-α-induced neutrophil priming in macrophage activation syndrome associated with systemic lupus erythematosus: Clinical and experimental insights
Objectives: To clarify the diagnostic utility of serum calprotectin and gene expression in interferon (IFN)-α-activated neutrophils in macrophage activation syndrome (MAS) in patients with systemic lupus erythematosus (SLE). Methods: This single-centre, cross-sectional study analysed serum calprotectin levels in 47 patients with SLE (including eight with MAS) and 7 patients with adult-onset Still’s disease (AOSD) complicated with MAS as a reference population. In neutrophil-based experiments, mRNA expression levels of S100A8 and S100A9 were measured following stimulation with IFN-α or interleukin (IL)-1β. Results: Serum calprotectin levels were significantly elevated in patients with SLE-MAS compared to those with SLE without MAS and comparable to those in patients with AOSD-MAS. Calprotectin levels correlated with serum ferritin levels (rs = 0.49, P = .004), but not with anti-dsDNA antibodies or complement levels. At a cut-off value of 9184.4 ng/ml, serum calprotectin demonstrated sensitivity of 62.5% and specificity of 94.9% for identifying MAS. Recombinant IFN-α2a induced a dose-dependent increase in S100A8 and S100A9 expression in neutrophils, whereas recombinant interleukin-1β had no effect. Pre-treatment with an anti-IFN-α2 neutralising antibody effectively suppressed the IFN-α2a-induced expression of S100A8 and S100A9. Conclusions: Serum calprotectin, upregulated by IFN-α, may serve as a useful biomarker for diagnosing MAS in SLE.
- Open Access
- 1 July 2021
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 8 (3) , 181
Claw hand deformity in longstanding vasculitic neuropathy
Cite this article as: Hosokawa Y, Oiwa H. Claw hand deformity in longstanding vasculitic neuropathy. Eur J Rheumatol 2021; 8(3): 181.
- 1 July 2021
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 8 (3) , 181
Open AccessClaw hand deformity in longstanding vasculitic neuropathy
Cite this article as: Hosokawa Y, Oiwa H. Claw hand deformity in longstanding vasculitic neuropathy. Eur J Rheumatol 2021; 8(3): 181.